| Symbol | BDRX |
|---|---|
| Name | BIODEXA PHARMACEUTICALS PLC |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1 CASPIAN POINT,CASPIAN WAY, CARDIFF, CF10 4DQ, United Kingdom |
| Telephone | +44 2920480180 |
| Fax | — |
| — | |
| Website | https://www.biodexapharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Companys lead development programs include eRapa, in Phase 3 development for Familial Adenomatous Polyposis; tolimidone, in Phase 2 development for the treatment of type 1 diabetes; and MTX110, in Phase 1 development in aggressive rare/orphan brain cancer indications. Additional info from NASDAQ: |
New Form 424B3 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214659-26-004254 <b>Size:</b> 549 KB
Read moreNew Form 424B3 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214659-26-004256 <b>Size:</b> 550 KB
Read moreNew Form 424B3 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214659-26-004255 <b>Size:</b> 589 KB
Read moreNew Form 424B3 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214659-26-004258 <b>Size:</b> 566 KB
Read moreNew Form 424B3 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214659-26-004253 <b>Size:</b> 653 KB
Read moreNew Form 424B3 - Biodexa Pharmaceuticals Plc <b>Filed:</b> 2026-04-02 <b>AccNo:</b> 0001214659-26-004257 <b>Size:</b> 648 KB
Read moreBiodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies
Read moreTanner Pharma Group e Biodexa lanciano il programma globale di accesso anticipato per i pazienti affetti da FAP
Read moreTanner Pharma Group en Biodexa lanceren wereldwijd programma voor vroegtijdige toegang voor FAP-patiënten
Read moreTanner Pharma Group y Biodexa lanzan un programa de acceso anticipado global para pacientes de poliposis adenomatosa familiar
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05324501 | A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Gliobla… | Phase1 | Recurrent Glioblastoma | Terminated | 2022-10-19 | 2024-09-10 | ClinicalTrials.gov |